Secondary analysis of 765 tumours from the SweBCG91RT trial (whole-breast RT vs none after breast-conserving surgery, node-negative stage I–IIA): the prostate-derived PORTOS signature predicted RT benefit for 10-year any recurrence (interaction P=0.049).
Secondary analysisn = 765 tumour samples
Zhao et al. Investigation of a Prostate Cancer Radiation Response Signature in the Breast Cancer SweBCG91RT Randomized Trial